Overview

The Use of Midazolam and Remifentanil During Dialysis Access Procedures

Status:
Completed

Trial end date:
2016-04-30

Target enrollment:
0

Participant gender:
All

Summary

BACKGROUND: Sedation and analgesia are related to unexpected adverse events in chronic renal failure patients undergoing arteriovenous fistula placement procedures under monitored anesthesia care (MAC). OBJECTIVE: Our goal was to investigate and compare the sedation and analgesia related effects and adverse effects of continuous intravenous use of midazolam and intermittent bolus doses of midazolam while intravenous remifentanil is used as a rescue medication in patients with chronic renal failure.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital

Collaborator:

Trakya University

Treatments:

Midazolam
Remifentanil

Criteria

Inclusion Criteria:

1. Age: Forty-three to eighty-one years of age,

2. ASA status: American Society of Anesthesiologist (ASA) status I-III,

3. The diagnosis: A diagnosis of chronic renal failure,

4. The operation type: An arteriovenous fistula procedure

Exclusion Criteria:

1. Body mass index greater than 40 that are considered morbidly obese patients,

2. Lung disorders leading to severe respiratory insufficiency such as; severe asthma,
chronic obstructive lung disease,

3. Severe cardiovascular insufficiency or dysfunction,

4. Insulin-dependent diabetes mellitus,

5. Severe hepatic diseases,

6. ASA status of 4 and 5,

7. Neurologic disorders such as; the presence of epilepsy, arterial aneurysm,
intracranial mass,

8. Patients complaining about intense pain before the procedure and patients with a
history of long term opioid use or chronic pain,

9. Patients with a history of allergy to the study drugs,

10. Patients without written informed consent.